Authors: Burke, TA Zabinski, RA Pettitt, D Maniadakis, N Maurath, CJ Goldstein, JL

Citation: Ta. Burke et al., A framework for evaluating the clinical consequences of initial therapy with NSAIDs, NSAIDs plus gastroprotective agents, or celecoxib in the treatment of arthritis, PHARMACOECO, 19(1), 2001, pp. 33-47

Authors: Zabinski, RA Burke, TA Johnson, J Lavoie, F Fitzsimon, C Tretiak, R Chancellor, JVM

Citation: Ra. Zabinski et al., An economic model for determining the costs and consequences of using various treatment alternatives for the management of arthritis in Canada, PHARMACOECO, 19(1), 2001, pp. 49-58

Authors: Bensen, WG Zhao, SZ Burke, TA Zabinski, RA Makuch, RW Maurath, CJ Agrawal, NM Geis, GS

Citation: Wg. Bensen et al., Upper gastrointestinal tolerability of celecoxib, a COX-2 specific inhibitor, compared to naproxen and placebo, J RHEUMATOL, 27(8), 2000, pp. 1876-1883